Patent ID: 9114081
Filing Date: 2015-08-25
Classification: A61K,A61P

Abstract:
1. A method for improving lung function in a human patient suffering from a Pseudomonas aeruginosa infection, the method comprising administering to the human patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein the at least one treatment cycle comprises an administration period of 20 to 35 days, followed by an off period of 25 to 75 days, during which an improvement in lung function is maintained for at least 15 days after the administration period ends, wherein the improvement in lung function comprises an increase in Forced Expiratory Volume in one second (FEV wherein the lipid component of the liposome comprises dipalmitoylphosphatidylcholine (DPPC) and cholesterol, and the effective dose comprises 510 mg to 610 mg of amikacin daily during the administration period.